Eduardo Cervantes-Alvarez

Dr. Eduardo Cervantes-Alvarez

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Eduardo Cervantes-AlvarezEduardo Cervantes-Alvarez
Eduardo Cervantes-Alvarez
NRNathaly Limon-De la Rosa
Nathaly Limon-De la Rosa
MMMoises Salgado-De la Mora
Moises Salgado-De la Mora
PVPaola Valdez-Sandoval
Paola Valdez-Sandoval
MPMildred Palacios-Jimenez
Mildred Palacios-Jimenez
NNNalu Navarro-Alvarez
Nalu Navarro-Alvarez
Severe COVID-19 is associated with a systemic hyperinflammatory response leading to acute respiratory distress syndrome (ARDS), multi-organ failure, and death. Galectin-3 is a ß-galactoside binding lectin known to drive neutrophil infiltration and the release of pro-inflammatory cytokines contributing to airway inflammation. Thus, we aimed to investigate the potential of galectin-3 as a biomarker of severe COVID-19 outcomes. We prospectively included 156 patients with RT-PCR confirmed COVID-19. A severe outcome was defined as the requirement of invasive mechanical ventilation (IMV) and/or in-hospital death. A non-severe outcome was defined as discharge without IMV requirement. We used receiver operating characteristic (ROC) and multivariable logistic regression analysis to determine the prognostic ability of serum galectin-3 for a severe outcome. Galectin-3 levels discriminated well between severe and non-severe outcomes and correlated with markers of COVID-19 severity, (CRP, NLR, D-dimer, and neutrophil count). Using a forward-stepwise logistic regression analysis we identified galectin-3 [odds ratio (OR) 3.68 (95% CI 1.47–9.20),p < 0.01] to be an independent predictor of severe outcome. Furthermore, galectin-3 in combination with CRP, albumin and CT pulmonary affection > 50%, had significantly improved ability to predict severe outcomes [AUC 0.85 (95% CI 0.79–0.91,p < 0.0001)]. Based on the evidence presented here, we recommend clinicians measure galectin-3 levels upon admission to facilitate allocation of appropriate resources in a timely manner to COVID-19 patients at highest risk of severe outcome.

26 May 2017 in Organogenesis
Verified
Journal Article
Open access
YWYang Wang
Yang Wang
KTKazuki Takeishi
Kazuki Takeishi
ZLZhao Li
Zhao Li
Eduardo Cervantes-AlvarezEduardo Cervantes-Alvarez
Eduardo Cervantes-Alvarez
ALAlexandra Collin de L'HOrtet
Alexandra Collin de L'HOrtet
JZJiye Zhu
Jiye Zhu
Organ-like microenviroment and 3-dimensional (3D) cell culture conformations have been suggested as promising approaches to mimic in a micro-scale a whole organ cellular functions and interactions present in vivo. We have used this approach to examine biologic features of hepatocellular carcinoma (HCC) cells. In this study, we demonstrate that hepatocellular carcinoma (HCC) cells, fibroblasts, endothelial cells and extracellular matrix can generate organoid-like spheroids that enhanced numerous features of human HCC observed in vivo. We show that the addition of non-parenchymal cells such as fibroblast and endothelial cells is required for spheroid formation as well as the maintenance of the tissue-like structure. Furthermore, HCC cells cultured as spheroids with non-parenchymal cells express more neo-angiogenesis-related markers (VEGFR2, VEGF, HIF-α), tumor-related inflammatory factors (CXCR4, CXCL12, TNF-α) and molecules-related to induced epithelial-mesenchymal transition (TGFβ, Vimentin, MMP9) compared with organoids containing only HCC cells. These results demonstrate the importance of non-parenchymal cells in the cellular composition of HCC organoids. The novelty of the multicellular-based organotypic culture system strongly supports the integration of this approach in a high throughput approach to identified patient-specific HCC malignancy and accurate anti-tumor therapy screening after surgery.

23 March 2018 in Hepatology Communications
Verified
Journal Article
Open access
PDF file
JGJorge Guzman‐Lepe
Jorge Guzman‐Lepe
Eduardo Cervantes-AlvarezEduardo Cervantes-Alvarez
Eduardo Cervantes-Alvarez
ALAlexandra Collin de L'Hortet
Alexandra Collin de L'Hortet
YWYang Wang
Yang Wang
WMWendy M. Mars
Wendy M. Mars
ASAlejandro Soto-Gutierrez
Alejandro Soto-Gutierrez
The mechanisms by which the liver fails in end‐stage liver disease remain elusive. Disruption of the transcription factor network in hepatocytes has been suggested to mediate terminal liver failure in animals. However, this hypothesis remains unexplored in human subjects. To study the relevance of transcription factor expression in terminal stages of chronic liver failure in humans, we analyzed the expression of liver‐enriched transcription factors (LETFs) hepatocyte nuclear factor (HNF)4α, HNF1α, forkhead box protein A2 (FOXA2), CCAAT/enhancer‐binding protein (CEBP)α, and CEBPβ. We then selected downstream genes responsible for some hepatic functions (ornithine transcarbamylase [OTC], cytochrome P450 3A4 [CYP3A4], coagulation factor VII [F7], cadherin 1 [CDH1], phospho‐ezrin (Thr567)/radixin (Thr564)/moesin (Thr558) [p‐ERM], phospho‐myosin light chain [p‐MLC], low‐density lipoprotein receptor‐related protein 1 [LRP1]) in liver tissue from patients at different stages of decompensated liver function based upon Child‐Pugh classification, Model for End‐Stage Liver Disease score, and degree of inflammatory activity/fibrosis. We first examined differential expression of LETF and determined whether a relationship exists between transcript and protein expression, and liver function. We found HNF4α expression was down‐regulated and correlated well with the extent of liver dysfunction (P =0.001), stage of fibrosis (P =0.0005), and serum levels of total bilirubin (P =0.009;r =0.35), albumin (P< 0.001;r =0.52), and prothrombin time activity (P =0.002;r =0.41). HNF4α expression also correlated with CYP3A4, OTC, and F7 as well as CDH1 RNA levels. The Rho/Rho‐associated protein kinase pathways, which have been implicated in the regulation of HNF4α, were also differentially expressed, in concert with LRP1, a reported upstream regulator of RhoA function.Conclusion:HNF4α and other members of the LETFs appear to be important regulators of hepatocyte function in patients with chronic hepatic failure. (Hepatology Communications2018;2:582‐594)

1 August 2020 in Seminars in Liver Disease
Verified
Journal Article
Closed access
PDF file
MLMaria J. Lizardo-Thiebaud
Maria J. Lizardo-Thiebaud
Eduardo Cervantes-AlvarezEduardo Cervantes-Alvarez
Eduardo Cervantes-Alvarez
NRNathaly Limon-De la Rosa
Nathaly Limon-De la Rosa
FTFarid Tejeda-Dominguez
Farid Tejeda-Dominguez
MPMildred Palacios-Jimenez
Mildred Palacios-Jimenez
NNNalu Navarro-Alvarez
Nalu Navarro-Alvarez
Liver injury can result from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with more than one-third of COVID-19 patients exhibiting elevated liver enzymes. Microvesicular steatosis, inflammation, vascular congestion, and thrombosis in the liver have been described in autopsy samples from COVID-19 patients. Several factors, including direct cytopathic effect of the virus, immune-mediated collateral damage, or an exacerbation of preexisting liver disease may contribute to liver pathology in COVID-19. Due to its immunological functions, the liver is an organ likely to participate in the viral response against SARS-CoV-2 and this may predispose it to injury. A better understanding of the mechanism contributing to liver injury is needed to develop and implement early measures to prevent serious liver damage in patients suffering from COVID-19. This review summarizes current reports of SARS-CoV-2 with an emphasis on how direct infection and subsequent severe inflammatory response may contribute to liver injury in patients with and without preexisting liver disease. * Contributed equally to this manuscript. Publication Date: 04 September 2020 (online) © 2020. Thieme. All rights reserved. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

1 May 2021 in Annals of Hepatology
Verified
Journal Article
Open access
OMOsvely Méndez-Guerrero
Osvely Méndez-Guerrero
DCDaniel A. Calle-Rodas
Daniel A. Calle-Rodas
Eduardo Cervantes-AlvarezEduardo Cervantes-Alvarez
Eduardo Cervantes-Alvarez
EAElisa Alatorre-Arenas
Elisa Alatorre-Arenas
JPJuanita Pérez-Escobar
Juanita Pérez-Escobar
ATAldo Torre
Aldo Torre
Acute on Chronic Liver Failure (ACLF) is characterized by organ failure and high 28-day mortality. Identifying clinical predictors associated with early mortality could have implications for the treatment of patients with ACLF. Patients diagnosed with chronic liver failure that developed ACLF based on the EASL-CLIF Consortium definition admitted to the Intensive care unit of a tertiary hospital between 2012-2018 were included. Bivariate and multivariate Cox regression analyses were performed to identify factors associated with mortality. 148 patients (55% female) were diagnosed with ACLF of which 55% (n = 82) had ACLF grade 3, 28% (n = 41) grade 2 and 17% (n = 25) grade 1. The median age was 54 years (41-63). Hepatitis C virus (HCV) was the most frequent etiology in 29.8% (n = 44) of the patients with bacterial infection being the most predominant precipitant factor in 58.1% (n = 86). Ninety-day global cumulative survival was only 18%. When divided by grade, mortality reached to 10% in ACLF 3. Moreover, in the multivariate Cox regression analysis, renal failure (HR 3.26, 95% CI (2.13-4.99), brain failure (HR 1.37, 95% CI 1.09-2.04) and male sex (HR 1.62, 95% CI 1.10-2.40) were independent predictors of 28- and 90-day mortality. ACLF is a frequent syndrome among chronic liver disease patients. Brain and renal failure are significantly associated with higher mortality and are independent predictors of 28 and 90-day mortality.

1 January 2015 in World Journal of Gastrointestinal Surgery
Verified
Journal Article
Open access
MMMiguel-Angel Mercado
Miguel-Angel Mercado
MVMario Vilatoba
Mario Vilatoba
ACAlan Contreras
Alan Contreras
PLPilar Leal-Leyte
Pilar Leal-Leyte
Eduardo Cervantes-AlvarezEduardo Cervantes-Alvarez
Eduardo Cervantes-Alvarez
BGBruno-Adonai Gonzalez
Bruno-Adonai Gonzalez
AIM: To describe our experience concerning the surgical treatment of Strasberg E-4 (Bismuth IV) bile duct injuries. METHODS: In an 18-year period, among 603 patients referred to our hospital for surgical treatment of complex bile duct injuries, 53 presented involvement of the hilar confluence classified as Strasberg E4 injuries. Imagenological studies, mainly magnetic resonance imaging showed a loss of confluence. The files of these patients were analyzed and general data were recorded, including type of operation and postoperative outcome with emphasis on postoperative cholangitis, liver function test and quality of life. The mean time of follow-up was of 55.9 ± 52.9 mo (median = 38.5, minimum = 2, maximum = 181.2). All other patients with Strasberg A, B, C, D, E1, E2, E3, or E5 biliary injuries were excluded from this study. RESULTS: Patients were divided in three groups: G1 (n = 21): Construction of neoconfluence + Roux-en-Y hepatojejunostomy. G2 (n = 26): Roux-en-Y portoenterostomy. G3 (n = 6): Double (right and left) Roux-en-Y hepatojejunostomy. Cholangitis was recorded in two patients in group 1, in 14 patients in group 2, and in one patient in group 3. All of them required transhepatic instrumentation of the anastomosis and six patients needed live transplantation. CONCLUSION: Loss of confluence represents a surgical challenge. There are several treatment options at different stages. Roux-en-Y bilioenteric anastomosis (neoconfluence, double-barrel anastomosis, portoenterostomy) is the treatment of choice, and when it is technically possible, building of a neoconfluence has better outcomes. When liver cirrhosis is shown, liver transplantation is the best choice.